Drug Profile
Lintuzumab Ac 225 - Actinium Pharmaceuticals
Alternative Names: 225Ac-HuM-195; 225Ac-lintuzumab; Ac-225-Lintuzumab; AC225 MOAB M195; Ac225 monoclonal antibody M195; Actimab-A; Actimab-M; Actimab-MDS; Actinium-225 (225Ac)-Lintuzumab; Actinium-225-labelled HuM195; HuM195-Ac-225Latest Information Update: 14 Dec 2023
Price :
$50
*
At a glance
- Originator PDL BioPharma
- Developer Actinium Pharmaceuticals; Baylor Research Institute; Memorial Sloan-Kettering Cancer Center; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia
- Preclinical Solid tumours
- No development reported Multiple myeloma; Myelodysplastic syndromes
Most Recent Events
- 11 Dec 2023 Adverse event data from a phase I/II trial in acute myeloid leukemia released by Actinium Pharmaceuticals
- 09 Dec 2023 Efficacy data from a phase I/II trial in Acute myeloid leukemia presented at 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 06 Nov 2023 Pharmacodynamics data from preclinical trial in Solid tumours released by Actinium Pharmaceuticals